Pfizer Inc PFE

$29.36 +0.13 (0.44%)

Valuation

Market cap
166,606,736,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.64
P/E (forward)
9.66
Profit margin
12.42%
Debt to equity
0.70

Trading

Volume
31,128,700
Avg volume
33,692,605
Day's range
$28.95 – $29.38
Shares out
5,699,854,000
Stochastic %K
28%
Beta
0.31
Analysts
Hold
Price target
$30.38

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

GTA_Terminal Nov 10, 11:32 PM
$PFE shares rose 0.44% to $29.36, with $1.6M going through the options. That breaks down to $185K in calls and $1.4M in puts, with puts carrying 88% of the money. Volume beat open interest in one contract, a sign that new money opened positions today. On the dark pool side, Monday (Nov 9) saw 18.7M shares off-exchange (40.8% of volume), 0.9x normal. A strongly bearish tilt in the options, with dark pools close to their usual level: one side committed, the other neutral for now.
0 replies
Comicguy Nov 10, 8:58 PM
$PFE Close strong baby.
1 replies
BuyHi Nov 10, 8:19 PM
$PFE cmon do something irrational for once
0 replies
Comicguy Nov 10, 8:03 PM
$PFE dPrice is now at the pper bollinger bands with the moving averages right underneath. Boom baby.
0 replies
Stocks_Spot Nov 10, 7:47 PM
$PFE raised its 2026 outlook on Nov 3, yet the stock has slipped since. Q3 adjusted EPS of $0.87 beat the ~$0.73 consensus on $16.6B in revenue, roughly flat year over year. 2026 revenue guidance rose to $62–64B and adjusted EPS to $2.95–3.05. The growth engine is newer drugs: launched and acquired products grew 32% operationally to $3.8B, nearly a quarter of sales. Eliquis rose 25% to $2.52B, driven mainly by higher U.S. net pricing. The problem is the cliff. About $22.7B of revenue faces U.S. patent expiry by 2028, including Eliquis (settled generic entry April 2028), Ibrance and Xtandi. Pfizer's answer is obesity: the $8B Metsera deal and 10 Phase 3 studies of monthly berobenatide planned for 2026. Can new launches and obesity outrun the patent cliff? Not financial advice. Do your own research.
0 replies
Comicguy Nov 10, 7:42 PM
$PFE Here we go.
0 replies
ddirk Nov 10, 7:37 PM
$PFE $NVAX Im from novavax what ai understand that we are using matrix-m to strengthen some of the current pfe vaccines and make $ for both companies. Does anyone have any insight?
1 replies
Comicguy Nov 10, 6:53 PM
$PFE Curling
0 replies